Detailed price information for Lowe's Companies (LOW-N) from The Globe and Mail including charting and trades.

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...

Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...

Shares of Eli Lilly (NYSE: LLY) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker with ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Eli Lilly’s weight-loss pill enthusiasm wanes, impacting its stock. Early trading on August 8 saw the company's stock down by ...

During a 72-week study, those taking the highest dose of orforglipron lost an average of 27.3 pounds. While injections might cause people to lose more weight, a pill has advantages over them, ...

Note that some links may require registration or subscription. The Trump administration is set to announce a proposed rule ...

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...